Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in Unruptured Vertebrobasilar Dissecting Aneurysms
NCT06405971Recruiting
- Start
- Jun 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of liquid metformin (Aspargo Labs) in dissecting aneurysm (2 arms). Primary endpoint: 3-dimensional wall enhancement volume rate at 6 months. Started Jun 2024; status: recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
dissecting aneurysm
Beyond the preview
Go deeper on NCT06405971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06405971.